Clinical Trial Update: Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing detection of metastases using PyL PET/CT in patients starting enzalutamide for untreated castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)

Snippet

Sponsor: CHU de Quebec-Universite Laval | Conditions: Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING